A triple-sized weekly dose of Ozempic works better to help people with obesity shed excess pounds without significant side effects, new clinical trial results show.
Obese folks lost more weight taking 7.2 mg of semaglutide (Ozempic/Wegovy) a week than those taking either the currently approved dose of 2.4 mg or a placebo, researchers reported Sept. 14 in The Lancet Diabetes & Endocrinology.
The results "suggest that a higher dose of semaglutide up to 7.2 mg per week could be used to achieve greater clinical benefits in people not reaching therapeutic goals with once-weekly semaglutide 2.4 mg," concluded a team led by Dr. Sean Wharton, leader of the Wharton Medical Clinic for Weight and Diabetes Management in Ontario, Canada.
Researchers tested the triple-dose of semaglutide in two clinical trials, one involving people with obesity and the other in people with obesity and type 2 diabetes.
Related
